Developer docs
API playgroundTry for free, no card

Search company profiles

Celegence

Full company profile

uuid00067dd

Namestring
Celegence
Legal namestring
CELEGENCE LLC
Websiteurl
celegence.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Celegence is a US-headquartered life sciences regulatory solutions provider founded in 2017 and operated as CELEGENCE LLC, delivering consulting services and proprietary technology to pharmaceutical manufacturers and medical device/IVD companies. Its core offering combines SME-led regulatory consulting — covering eCTD submissions, regulatory writing, CMC technical writing, medical writing, RIMS management, regulatory affairs consulting, and regulatory intelligence — with three proprietary technology products: CAPTIS®, an in-house AI platform for automated authoring of EU MDR/IVDR documentation including CERs, PMCF plans/reports, CEPs, PEPs, and SSCPs; Dossplorer™, a cloud-based eCTD viewer and dossier manager acquired from Qdossier in July 2022; and Dosscriber™, MS Word-based eCTD document templates. The technology stack is supported by an engineering and delivery center in Cluj, Romania, while consulting delivery is distributed across offices in the USA (Downers Grove), UK (London), Netherlands (Waalwijk), India (Bangalore), Japan (Tokyo), and Brazil.

The business model blends professional services revenue (project-based and multi-year enterprise engagements) with recurring SaaS subscription access to the CAPTIS platform and technology licensing for Dossplorer and Dosscriber. Pricing is quote-based and not publicly disclosed, with multi-year contract cadences typical for enterprise engagements. Go-to-market is direct enterprise sales targeting regulatory affairs leaders, quality assurance executives, and compliance officers at pharma and medtech manufacturers; named customers include Johnson & Johnson, AstraZeneca, Novartis, Gilead Sciences, Baxter, Cook Medical, Bausch Health, Alcon, Otsuka, Regeneron, and Philips Healthcare. The company holds ISO 9001, 14001, 45001, and 27001:2022 certifications, NMSDC Certified-MBE status (2022), and WBE certification, and maintains a global partnership footprint anchored by premier sponsorship of RAPS US Convergence and active participation in DIA and MedTech Summit industry events.

Short descriptiontext

Celegence provides tech-enabled regulatory affairs services and compliance technology for pharmaceutical and medical device/IVD manufacturers globally, combining proprietary AI tools (CAPTIS®), cloud dossier management (Dossplorer™), and SME-led consulting across eCTD submissions, clinical evaluation reports, and EU MDR/IVDR compliance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDowners Grove, United States
HQ citystring
Downers Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, medical device compliance, pharmaceutical submissions services, eCTD publishing solutions, EU MDR IVDR compliance
Industry1 code
PRIMARYHLAGAKAC
Regulatory Operations & Publishing (eCTD, RIM, Submission Management)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Management Consulting Services54161
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences Regulatory Affairs Consulting and Compliance Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Regulatory Consulting Services
TypeProfessional Services
Description

Professional consulting services including regulatory strategy, submissions management, clinical evaluation, and compliance support for pharmaceutical and medical device companies. Services delivered by SMEs with advanced degrees and extensive industry experience.

celegence.com
2AI Technology Platform Subscription
TypeSubscription Recurring
Description

SaaS subscription access to CAPTIS® AI platform for automated medical writing and documentation. Technology platform enables faster turnaround and reduced compliance burden for clients.

celegence.com
3Regulatory Technology Tools
TypeSubscription Recurring
Description

Access to proprietary tools including Dossplorer™ for dossier management and Dosscriber™ for document templates. Technology licensing provides ongoing value for regulatory operations.

celegence.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise regulatory services with customized pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Pricing varies based on service scope, complexity, regulatory region, and project duration.

celegence.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1CAPTIS®
Description

AI-powered regulatory compliance technology platform designed to streamline medical writing and documentation processes for EU MDR/IVDR compliance, including CEP/CER, PEP/PER, PMCF plans/reports, and SSCPs.

celegence.com
+2 more records
Core offering1 text field

Celegence provides tech-empowered regulatory affairs consulting and compliance services to pharmaceutical, medical device, and in-vitro diagnostics manufacturers globally. Its offering combines SME-led regulatory consulting across submissions, clinical evaluation, post-market surveillance, and data governance with proprietary AI-enabled technology platforms (CAPTIS®, Dossplorer™, Dosscriber™) that automate medical writing, dossier management, and eCTD document preparation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 50% faster delivery with intact quality
+6 more records
Product overview1 text field

Celegence offers a tech-empowered regulatory services platform combining proprietary AI solutions with expert consulting for pharmaceutical and medical device companies. The core platform consists of three main proprietary products: CAPTIS® AI Platform (in-house AI for medical writing and documentation automation), Dossplorer™ Cloud eCTD Viewer & Manager (acquired from Qdossier in 2022), and Dosscriber™ eCTD Document Templates. These technology products are supported by an integrated suite of consulting services spanning regulatory publishing, regulatory writing, CMC technical writing, medical writing, RIMS management, data governance, regulatory affairs consulting, regulatory intelligence, and combination products services. For medical devices and IVDs, services include EU MDR/IVDR consulting, post-market surveillance, PMCF, clinical evaluation reports, systematic literature reviews, US FDA consulting, and technical file/DMR remediation. The company leverages its AI platform to automate complex content authoring processes, enabling faster, higher-quality deliverables with greater transparency and reduced compliance burden.

Product and service1 record
1CAPTIS® AI Platform
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-18
Description

Celegence acquired Qdossier, a provider of document and dossier management services for the pharmaceutical industry. The acquisition included integration of Qdossier's cloud-based technology, Dossplorer, expanding Celegence's technological and consulting offerings worldwide. The integration enables proactive, personalized support for clients in product approval and market maintenance.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialist regulatory, medical affairs and compliance consulting firm serving pharma and MedTech — closely aligned service catalog and target customers as Celegence, with a similar mid-sized boutique positioning.

TypeDirect peer
Description

Regulatory and clinical consulting firm specializing in health authority interactions, submissions and clinical evaluation reports — comparable to Celegence's EU MDR/IVDR and pharma regulatory services.

TypeBroad incumbent
Description

Large CRO with dedicated regulatory and medical writing/affairs services, competing for the same pharma and MedTech enterprise clients as Celegence.

TypeBroad incumbent
Description

Global CRO and life sciences services giant offering regulatory affairs, eCTD publishing, RIMS, and increasingly GenAI-enabled medical writing — overlaps with Celegence's pharma services but at vastly larger scale and broader portfolio.

TypeEmerging player
Description

AI-driven regulatory intelligence and submission management platform for MedTech and IVD — emerging tech-native competitor to Celegence's CAPTIS AI and Dossplorer stack.

TypeBroad incumbent
Description

Global CRO with strong regulatory consulting, eCTD publishing and clinical evaluation report practices — directly competes for the same EU MDR/IVDR and pharma submission work.

TypeEmerging player
Description

Provider of RIMS, regulatory content management and AI-augmented regulatory workflows — competes with Celegence's Dossplorer/RIMS management and emerging AI capabilities.

TypeDirect peer
Description

Regulatory affairs and pharmacovigilance services provider for pharma and biotech; competes head-to-head with Celegence on EU submissions, CMC writing and regulatory strategy.

TypeBroad incumbent
Description

Large CRO with regulatory operations, eCTD publishing and clinical development services — competing for enterprise pharma and MedTech regulatory outsourcing spend.

TypeBroad incumbent
Description

Life sciences services firm with regulatory and safety/medical writing offerings, serving large pharma and medical device manufacturers — adjacent competitor in regulatory services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers18 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celegence

Life Sciences Regulatory Affairs Consulting and Compliance Servicescelegence.com

Celegence provides tech-enabled regulatory affairs services and compliance technology for pharmaceutical and medical device/IVD manufacturers globally, combining proprietary AI tools (CAPTIS®), cloud dossier management (Dossplorer™), and SME-led consulting across eCTD submissions, clinical evaluation reports, and EU MDR/IVDR compliance.

What Celegence does

Celegence is a US-headquartered life sciences regulatory solutions provider founded in 2017 and operated as CELEGENCE LLC, delivering consulting services and proprietary technology to pharmaceutical manufacturers and medical device/IVD companies. Its core offering combines SME-led regulatory consulting — covering eCTD submissions, regulatory writing, CMC technical writing, medical writing, RIMS management, regulatory affairs consulting, and regulatory intelligence — with three proprietary technology products: CAPTIS®, an in-house AI platform for automated authoring of EU MDR/IVDR documentation including CERs, PMCF plans/reports, CEPs, PEPs, and SSCPs; Dossplorer™, a cloud-based eCTD viewer and dossier manager acquired from Qdossier in July 2022; and Dosscriber™, MS Word-based eCTD document templates. The technology stack is supported by an engineering and delivery center in Cluj, Romania, while consulting delivery is distributed across offices in the USA (Downers Grove), UK (London), Netherlands (Waalwijk), India (Bangalore), Japan (Tokyo), and Brazil.

The business model blends professional services revenue (project-based and multi-year enterprise engagements) with recurring SaaS subscription access to the CAPTIS platform and technology licensing for Dossplorer and Dosscriber. Pricing is quote-based and not publicly disclosed, with multi-year contract cadences typical for enterprise engagements. Go-to-market is direct enterprise sales targeting regulatory affairs leaders, quality assurance executives, and compliance officers at pharma and medtech manufacturers; named customers include Johnson & Johnson, AstraZeneca, Novartis, Gilead Sciences, Baxter, Cook Medical, Bausch Health, Alcon, Otsuka, Regeneron, and Philips Healthcare. The company holds ISO 9001, 14001, 45001, and 27001:2022 certifications, NMSDC Certified-MBE status (2022), and WBE certification, and maintains a global partnership footprint anchored by premier sponsorship of RAPS US Convergence and active participation in DIA and MedTech Summit industry events.

Celegence firmographics

Firmographics
Name
Celegence
Legal name
CELEGENCE LLC
Website
https://celegence.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Celegence provides tech-enabled regulatory affairs services and compliance technology for pharmaceutical and medical device/IVD manufacturers globally, combining proprietary AI tools (CAPTIS®), cloud dossier management (Dossplorer™), and SME-led consulting across eCTD submissions, clinical evaluation reports, and EU MDR/IVDR compliance.
Ownership category
akta.pro rank

Celegence industry classification

Industry
Product category
Life Sciences Regulatory Affairs Consulting and Compliance Services
NAICS
Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAC
Regulatory Operations & Publishing (eCTD, RIM, Submission Management)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Regulatory affairs consulting
  • Medical device compliance
  • Pharmaceutical submissions services
  • ECTD publishing solutions
  • EU MDR IVDR compliance

Where Celegence is headquartered

Location

Headquarters

HQ city
Downers Grove
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Celegence business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Regulatory Consulting Services: Professional consulting services including regulatory strategy, submissions management, clinical evaluation, and compliance support for pharmaceutical and medical device companies. Services delivered by SMEs with advanced degrees and extensive industry experience.
  2. AI Technology Platform Subscription: SaaS subscription access to CAPTIS® AI platform for automated medical writing and documentation. Technology platform enables faster turnaround and reduced compliance burden for clients.
  3. Regulatory Technology Tools: Access to proprietary tools including Dossplorer™ for dossier management and Dosscriber™ for document templates. Technology licensing provides ongoing value for regulatory operations.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise regulatory services with customized pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Celegence product offering

Product offering

Core offering

Celegence provides tech-empowered regulatory affairs consulting and compliance services to pharmaceutical, medical device, and in-vitro diagnostics manufacturers globally. Its offering combines SME-led regulatory consulting across submissions, clinical evaluation, post-market surveillance, and data governance with proprietary AI-enabled technology platforms (CAPTIS®, Dossplorer™, Dosscriber™) that automate medical writing, dossier management, and eCTD document preparation.

Product overview

Celegence offers a tech-empowered regulatory services platform combining proprietary AI solutions with expert consulting for pharmaceutical and medical device companies. The core platform consists of three main proprietary products: CAPTIS® AI Platform (in-house AI for medical writing and documentation automation), Dossplorer™ Cloud eCTD Viewer & Manager (acquired from Qdossier in 2022), and Dosscriber™ eCTD Document Templates. These technology products are supported by an integrated suite of consulting services spanning regulatory publishing, regulatory writing, CMC technical writing, medical writing, RIMS management, data governance, regulatory affairs consulting, regulatory intelligence, and combination products services. For medical devices and IVDs, services include EU MDR/IVDR consulting, post-market surveillance, PMCF, clinical evaluation reports, systematic literature reviews, US FDA consulting, and technical file/DMR remediation. The company leverages its AI platform to automate complex content authoring processes, enabling faster, higher-quality deliverables with greater transparency and reduced compliance burden.

Differentiator

Problem solved

Functional benefit

Brands

  • CAPTIS®: AI-powered regulatory compliance technology platform designed to streamline medical writing and documentation processes for EU MDR/IVDR compliance, including CEP/CER, PEP/PER, PMCF plans/reports, and SSCPs.
  • Dossplorer™
  • Dosscriber™

Products and services

  • CAPTIS® AI Platform

Quantifiable outcome

  • 50% faster delivery with intact quality
  • +6 more outcomes

Companies that use Celegence

Customer profile

Named customers18 records

Segments2 records

Ideal customer profiles2 records

Celegence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Celegence partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • QdossiercoreStrategic or Co-development Partner · 18 July 2022Celegence acquired Qdossier, a provider of document and dossier management services for the pharmaceutical industry. The acquisition included integration of Qdossier's cloud-based technology, Dossplorer, expanding Celegence's technological and consulting offerings worldwide. The integration enables proactive, personalized support for clients in product approval and market maintenance.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Celegence competitors and assessment

Company assessment

Direct peers

  • ProPharma Group: Specialist regulatory, medical affairs and compliance consulting firm serving pharma and MedTech — closely aligned service catalog and target customers as Celegence, with a similar mid-sized boutique positioning.
  • VCLS (Voisin Consulting Life Sciences): Regulatory and clinical consulting firm specializing in health authority interactions, submissions and clinical evaluation reports — comparable to Celegence's EU MDR/IVDR and pharma regulatory services.
  • Pharmalex: Regulatory affairs and pharmacovigilance services provider for pharma and biotech; competes head-to-head with Celegence on EU submissions, CMC writing and regulatory strategy.

Broad incumbents

  • ICON plc: Large CRO with dedicated regulatory and medical writing/affairs services, competing for the same pharma and MedTech enterprise clients as Celegence.
  • IQVIA: Global CRO and life sciences services giant offering regulatory affairs, eCTD publishing, RIMS, and increasingly GenAI-enabled medical writing — overlaps with Celegence's pharma services but at vastly larger scale and broader portfolio.
  • Parexel: Global CRO with strong regulatory consulting, eCTD publishing and clinical evaluation report practices — directly competes for the same EU MDR/IVDR and pharma submission work.
  • Labcorp Drug Development (Fortrea): Large CRO with regulatory operations, eCTD publishing and clinical development services — competing for enterprise pharma and MedTech regulatory outsourcing spend.
  • Charles River Laboratories: Life sciences services firm with regulatory and safety/medical writing offerings, serving large pharma and medical device manufacturers — adjacent competitor in regulatory services.

Emerging players

  • RegDesk: AI-driven regulatory intelligence and submission management platform for MedTech and IVD — emerging tech-native competitor to Celegence's CAPTIS AI and Dossplorer stack.
  • MediSpend (Pharmalex) / ArisGlobal: Provider of RIMS, regulatory content management and AI-augmented regulatory workflows — competes with Celegence's Dossplorer/RIMS management and emerging AI capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Celegence social profiles

Digital presence

Celegence compliance and trust

Trust signal

Compliance5 records

Celegence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celegence leadership team

Management profile

Number of profiles

Profiles17 records

Celegence subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Celegence funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celegence M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celegence

What does Celegence do?

Celegence provides tech-empowered regulatory affairs consulting and compliance services to pharmaceutical, medical device, and in-vitro diagnostics manufacturers globally. Its offering combines SME-led regulatory consulting across submissions, clinical evaluation, post-market surveillance, and data governance with proprietary AI-enabled technology platforms (CAPTIS®, Dossplorer™, Dosscriber™) that automate medical writing, dossier management, and eCTD document preparation.

Is Celegence a public or private company?

Celegence is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Celegence founded?

Celegence was founded in 2017. It employs 101 to 250 people.

Where is Celegence based?

Celegence is headquartered in Downers Grove, United States, in the North America region.

How does Celegence make money?

Three revenue lines are on record. Regulatory Consulting Services are the primary driver. The others are AI Technology Platform Subscription and regulatory Technology Tools.

Who are Celegence's main competitors?

Direct peers on record are ProPharma Group, VCLS (Voisin Consulting Life Sciences) and Pharmalex. Broad incumbents are ICON plc, IQVIA, Parexel, Labcorp Drug Development (Fortrea) and Charles River Laboratories. Emerging players are RegDesk and MediSpend (Pharmalex) / ArisGlobal.

Does Celegence have an API?

No public API is recorded for Celegence.

What industry is Celegence in?

Celegence's product category is Life Sciences Regulatory Affairs Consulting and Compliance Services. Its primary akta.pro industry code is HLAGAKAC, Regulatory Operations & Publishing (eCTD, RIM, Submission Management). Its NAICS code is 54169 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CelegenceRegulatory Affairs Consultancy and SupportCelegence provides regulatory consulting services to help pharmaceutical and biotech companies navigate the regulatory pathways for commercialization of medicinal products, ensuring compliance with health authorities such as the FDA, EMA, and Health Canada. Their services range from early-stage clinical trial applications to marketing authorization and lifecycle management, with a focus on speeding up the time to market for innovative therapies. The company aims to support clients in aligning their regulatory solutions with product innovation and patient benefits.CelegenceAI-Powered Medical Writing ServicesCelegence offers specialized regulatory medical writing and submission services to assist pharmaceutical companies with drug approval processes. The company provides end-to-end support for clinical documentation, pharmacovigilance, and regulatory documents, leveraging proprietary tools like Dossplorer™ and Dosscriber™ to streamline electronic Common Technical Document (eCTD) submissions.CelegenceRegulatory Approvals in Africa: Key Frameworks, Challenges, and Emerging TrendsThe article provides an overview of the complex and fragmented regulatory landscape for pharmaceutical approvals across African nations, highlighting key markets like South Africa, Nigeria, and Egypt. It details ongoing regional harmonization efforts, such as those by the African Medicines Agency (AMA) and various community blocs, while noting challenges including varying timelines and documentation requirements. Celegence is presented as a service provider assisting pharmaceutical companies in navigating these regulatory journeys through dossier preparation and compliance support.CelegenceAI and Data Privacy: Securing Compliance in Life SciencesCelegence has released a framework detailing how to implement secure, compliant AI solutions for the life sciences sector by integrating certified infrastructure and strict data privacy controls. The company utilizes Microsoft Azure OpenAI and Unstructured under zero-retention policies to process sensitive regulatory documentation while adhering to standards such as HIPAA, GDPR, and SOC 2.CelegenceRegulatory and Market Intelligence Support for a Top-Tier Biotechnology FirmCelegence was awarded a contract by a top-tier US biotechnology firm to provide regulatory and market intelligence services regarding pharmaceutical and medical device compliance. The project involved analyzing regulatory updates from authorities such as the FDA, HSA, and TGA across approximately 30 countries to assess impacts on product quality and market entry strategies. Celegence delivered comprehensive reports detailing registration requirements, risk mapping, and comparative analyses of global regulations to support the client's strategic decision-making.CelegenceMDR Made Easy: Helping MedTech Innovators Stay FDA CompliantThe article discusses the importance of FDA Medical Device Reporting (MDR) compliance for medical device manufacturers, highlighting how Celegence assists companies in navigating complex regulatory requirements. Celegence offers tailored strategies to enhance compliance capabilities, minimize risks, and ultimately protect patient safety and market trust. The article emphasizes that effective MDR compliance can also serve as a competitive advantage for companies in the MedTech industry.CelegenceLean Authoring for DMFs: Faster, Smarter Regulatory SubmissionsCelegence promotes the implementation of Lean Authoring principles to optimize the creation and submission of Drug Master Files (DMFs) for pharmaceutical companies. The article outlines strategies such as early submission, electronic formatting via eCTD, and improved cross-referencing to accelerate regulatory review timelines by global health authorities like the FDA, EMA, and PMDA.CelegenceCAPTIS® Transforms Regulatory Writing WorkflowsCelegence partnered with a global MedTech firm to implement its AI-powered CAPTIS® platform, transforming the client's regulatory writing workflows from fragmented manual processes to structured, automated systems. The solution provided real-time collaboration, version control, and automated formatting, resulting in faster turnaround times and improved compliance for regulatory submissions.CelegenceRPA in Regulatory Affairs: Benefits & Best PracticesThe article outlines strategic guidelines for implementing Robotic Process Automation (RPA) within regulatory affairs to replace manual, paper-driven workflows with automated digital processes. It details key benefits such as enhanced efficiency, cost savings, and improved compliance while providing a roadmap for identifying suitable tasks, validating systems under GxP standards, and integrating with AI. Celegence is presented as a partner offering expertise in deploying these automation solutions for pharmaceutical and medical device industries.PR NewswireFiling eCTD (electronic Common Technical Document) Submissions Training Course: Now Mandatory for Submissions in the EU and Global regulatory AgenciesResearchAndMarkets.com has added a one-day training course on eCTD submissions to its portfolio, aimed at regulatory professionals in the pharmaceutical industry. The course covers implementation of efficient processes for submitting electronic dossiers to regulatory agencies in the EU and US. Speakers from Qdossier, a Celegence company, will share practical experiences and validation criteria.